Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study

被引：0
|
作者：
Chiao-En Wu
Ching-Fu Chang
Chen-Yang Huang
Cheng-Ta Yang
Chih-Hsi Scott Kuo
Ping-Chih Hsu
John Wen-Cheng Chang
机构：
[1] Chang Gung University College of Medicine,Department of Internal Medicine, Division of Hematology
[2] Chang Gung University College of Medicine,Oncology, Chang Gung Memorial Hospital at Linkou
来源：
BMC Cancer | / 21卷
关键词：
Lung cancer; Afatinib; EGFR; TKI; Performance status;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
    Wu, Chiao-En
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Hsu, Ping-Chih
    Chang, John Wen-Cheng
    BMC CANCER, 2021, 21 (01)
  • [2] Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Golembesky, Amanda
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2018, 14 (27) : 2861 - 2874
  • [3] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
    Nakashima, Kazuhisa
    Kimura, Madoka
    Akamatsu, Hiroaki
    Daga, Haruko
    Imai, Hisao
    Taira, Tetsuhiko
    Ko, Ryo
    Hisamatsu, Yasushi
    Nishino, Kazumi
    Sugimoto, Takeya
    Miyashita, Yosuke
    Takahashi, Toshiaki
    Kumagai, Toru
    Yamamoto, Nobuyuki
    Murakami, Haruyasu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
  • [4] Update on afatinib-based combination regimens for the treatment of EGFR mutation-positive non-small-cell lung cancer
    Bennouna, Jaafar
    FUTURE ONCOLOGY, 2017, 13 (21) : 1829 - 1833
  • [5] Combination of afatinib with cetuximab in patients with EGFR-mutant non-small-cell lung cancer resistant to EGFR inhibitors
    Gomes, Jessica Ribeiro
    Cruz, Marcelo Rocha S.
    ONCOTARGETS AND THERAPY, 2015, 8 : 1137 - 1142
  • [6] Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: updated analysis of the observational GioTag study
    Hochmair, Maximilian J.
    Morabito, Alessandro
    Hao, Desiree
    Yang, Cheng-Ta
    Soo, Ross A.
    Yang, James C-H
    Gucalp, Rasim
    Halmos, Balazs
    Wang, Lara
    Maerten, Angela
    Cufer, Tanja
    FUTURE ONCOLOGY, 2019, 15 (25) : 2905 - 2913
  • [7] First-line osimertinib in EGFR mutation-positive non-small cell lung cancer patients with poor performance status
    Takamizawa, Shigemasa
    Okuma, Yusuke
    Kato, Yasuhiro
    Hakozaki, Taiki
    Kitagawa, Shingo
    Zenke, Yoshitaka
    FUTURE ONCOLOGY, 2021, 18 (03) : 291 - 300
  • [8] EGFR exon mutation distribution and outcome in non-small-cell lung cancer: a Portuguese retrospective study
    de Mello, Ramon Andrade
    Pires, Filipa Soares
    Marques, Dania Sofia
    Oliveira, Julio
    Rodrigues, Ana
    Soares, Marta
    Azevedo, Isabel
    Peixoto, Ana
    Santos, Catarina
    Pinto, Carla
    Hespanhol, Venceslau
    Teixeira, Manuel R.
    Amaro, Teresina
    Queiroga, Henrique
    Araujo, Antonio
    TUMOR BIOLOGY, 2012, 33 (06) : 2061 - 2068
  • [9] Comparing the effectiveness of different EGFR-TKIs in patients with EGFR mutant non-small-cell lung cancer: A retrospective cohort study in Taiwan
    Hsieh, Yao-Yu
    Fang, Wei-Tse
    Lo, Yu-Wen
    Chen, Yi-Han
    Chien, Li-Nien
    INTERNATIONAL JOURNAL OF CANCER, 2020, 147 (04) : 1107 - 1116
  • [10] EGFR mutation analysis in non-small-cell lung cancer
    Tapia, C.
    Savic, S.
    Bihl, M.
    Rufle, A.
    Zlobec, I.
    Terracciano, L.
    Bubendorf, L.
    PATHOLOGE, 2009, 30 (05): : 384 - 392
12345